Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/22/2005US20050281910 Method for increasing pet activity
12/22/2005US20050281903 Extract of Stephaniae sinica Diels and methods of using the same
12/22/2005US20050281899 Ginkgolides for inhibition of membrane expression of benzodiazepine receptors
12/22/2005US20050281897 Agent for preventing, improving or treating hypertension
12/22/2005US20050281896 Nutritional composition for increasing creatine uptake in skeletal muscle
12/22/2005US20050281892 Highly efficacious and highly safe composition of a Stilbene derivative and a platinum coordination compound cis-diaminedichloroplatinum (II)
12/22/2005US20050281891 Testosterone stimulant
12/22/2005US20050281889 Nutritional supplement for adults
12/22/2005US20050281888 Nutritional supplement for infants
12/22/2005US20050281875 Promethazine containing dosage form
12/22/2005US20050281873 Universal controlled-release composition
12/22/2005US20050281872 Enhanced compliance antiviral medicaments and methods of manufacture and use
12/22/2005US20050281870 Pain management
12/22/2005US20050281867 Nitric oxide inducing agents
12/22/2005US20050281864 comprises fatty acids; for treatment/prevention of sepsis or inflammatory shock
12/22/2005US20050281863 Controlled release bioactive agent delivery device
12/22/2005US20050281862 Non-aspirating transitional viscoelastics for use in surgery
12/22/2005US20050281861 Macromolecule-containing sustained release intraocular implants and related methods
12/22/2005US20050281856 Implantable biostructure comprising an osteoconductive member and an osteoinductive material
12/22/2005US20050281850 Cosmetic/dermatological inverse emulsions containing calcitriol and clobetasol 17-propionate
12/22/2005US20050281848 Oleaginous ointments comprising two solubilized bioactive agents for the treatment of psoriasis
12/22/2005US20050281839 Spirulina composition and antiallergic food
12/22/2005US20050281832 Methods of enhancing immune response in the intradermal compartment and compounds useful thereof
12/22/2005US20050281831 inhibiting vascularization or angiogenesis using chimeric proteins, immunoglobulin-like domains of tyrosine kinase receptors
12/22/2005US20050281824 Methods of using IMXP-888 and IMXP-888 antagonists
12/22/2005US20050281821 Binds to a denatured collagens but not to native triple helical forms of the collagen; antitumor agents, antimetastasis agents; monoclonal antibodies; drug screening for denatured collagen antagonists
12/22/2005US20050281820 Administering to a burn an anticytokine or antiinflammatory agent and a pharmaceutically excipient; administering to a mammal having a burn injury:sodium monofluorophosphate and a dihydrofolate reductase inhibitor of aminopterin, methotrexate, pyramethamine, trimethoprim or derivatives
12/22/2005US20050281797 Methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume, glue featuring an adhering moiety coupled to one or more other moieties including a cross-linkable moiety and/or one other adhering moiety; use in treating pulmonary conditions, emphysema, copd
12/22/2005US20050281796 Targeting damaged lung tissue
12/22/2005US20050281794 comprising a catechin (epigallocatechin gallate), an anti-oxidant (ascorbic acid), proline and lysine; cancer
12/22/2005US20050281777 Photo-triggered release of active substances from dendrimer-photosensitizer complexes
12/22/2005US20050281775 Mucoadhesive and bioadhesive polymers
12/22/2005US20050281766 Method of improving the aesthetic appearance of epithelia
12/22/2005US20050281764 Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin
12/22/2005US20050281762 Mixture containing water insoluble organozinc compound, panthenol and gelling agent; reduce skin sensitivity to therapy, hygiene products
12/22/2005US20050281761 Methods of preventing UVB-induced skin damage
12/22/2005US20050281755 Topical foam/mousse compositions for treating psoriasis
12/22/2005US20050281754 Sprayable compositions comprising a combination of pharmaceutical active ingredients, an alcohol phase and an oily phase
12/22/2005US20050281753 Buccal, polar and non-polar spray or capsule
12/22/2005US20050281750 Sprayable compositions comprising a combination of pharmaceutical active agents, an alcohol phase, at least one volatile silicone and a non-volatile oily phase
12/22/2005US20050281749 Sprayable compositions comprising a combination of pharmaceutical actives and an oily phase
12/22/2005US20050280960 Magnetic random access memory array with coupled soft adjacent magnetic layer
12/22/2005US20050279861 Catalyst solution dispenser for a hand-held liquid spraying apparatus
12/22/2005US20050279859 Method for introducing a catalyst solution into a coating formulation
12/22/2005US20050279280 Coating formulation kit including a catalyst solution dispenser for a hand-held liquid spraying apparatus
12/22/2005DE19814084B4 D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's disease and process for its preparation
12/22/2005DE19603788B4 Wirkstoffextrakt aus Teufelskrallenwurzel, diesen enthaltendes human- oder veterinärmedizinisches Präparat, Verfahren zur Herstellung eines hochkonzentrierten Extraktes aus Radix Harpagophyti oder Herba und Radix Scrophularia sowie dessen Verwendung Drug extract of devil's claw root, these containing human or veterinary medical preparation, method for producing a highly concentrated extract of Radix Harpagophyti or Herba and Radix Scrophularia and its use
12/22/2005DE102004027685A1 Method and composition useful e.g. to improve the symptoms of hypersensitive teeth or toothache comprises applying topical formulation comprising sodium-channel blockers (e.g. tetracaine or bupivacaine) and additives on the tooth surface
12/22/2005DE102004025552A1 New 2-amino-imidazo(4,5-d)pyridazin-4-one derivatives are dipeptidyl-peptidase IV inhibitors useful in the treatment of e.g. diabetes mellitus, autoimmune disease, rheumatoid arthritis, and multiple sclerosis
12/22/2005DE102004025535A1 Kombination von Salzen der o-Acetylsalicylsäure und Alpha-Glucosidase-Inhibitoren Combination of salts of o-acetylsalicylic acid and alpha-glucosidase inhibitors
12/22/2005DE102004024772A1 Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide Substituted 5-aminomethyl-1H-pyrrole-2-carboxylic acid
12/22/2005DE102004024451A1 Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten Powder formulations for inhalation which contain Enantiomerically pure beta agonists
12/22/2005DE10042412B4 Transceiver for bus subscriber of bus system of building system engineering, has two wires, where microcontroller is connected with receiver unit over connection on one hand, which is connected to two wires of bus system
12/22/2005CA2727841A1 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2, 3-d] pyrimidine derivatives and related compounds
12/22/2005CA2576236A1 1-`(3r)-amino-4-(2-fluoro-phenyl)-butyl !-pyrrolidine-(2r)-carboxilic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase iv (dpp-iv) inhibitors for the treatment of type 2 diabetes mellitus
12/22/2005CA2570073A1 Protein kinase inhibitors
12/22/2005CA2570046A1 Substituted triazole derivatives as oxytocin antagonists
12/22/2005CA2570042A1 Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
12/22/2005CA2570041A1 Process for the preparation of nateglinide
12/22/2005CA2569910A1 Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds
12/22/2005CA2569891A1 Glycosylphosphatidylinositol glycan signalling via integrins functioning as glycan specific receptors
12/22/2005CA2569887A1 Pyrrolopyridine derivatives
12/22/2005CA2569883A1 Aroyl-o-piperidine derivatives for the treatment of diabetes-related problems
12/22/2005CA2569843A1 New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
12/22/2005CA2569842A1 New substituted piperidines as modulators of dopamine neurotransmission
12/22/2005CA2569746A1 Capsule stable against mastication
12/22/2005CA2569743A1 Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
12/22/2005CA2569738A1 Dispenser for progestin used for acute and maintenance treatment of dub
12/22/2005CA2569686A1 Highly selective novel amidation method
12/22/2005CA2569678A1 Regulator of physiological function of ghrelin and use thereof
12/22/2005CA2569675A1 Cationic bacteriochlorophyll derivatives and uses thereof
12/22/2005CA2569672A1 Polypeptides with the capacity to entrap drugs and release them in a controlled way
12/22/2005CA2569664A1 Lipid encapsulated interfering rna
12/22/2005CA2569623A1 Novel compounds and use of tetrahydropyridothiophenes
12/22/2005CA2569590A1 Drug having regulatory cell ligand contained in liposome
12/22/2005CA2569535A1 Dpp-iv inhibitors
12/22/2005CA2569534A1 Dpp-iv inhibitors
12/22/2005CA2569411A1 Methods and compositions for treating mood disorder
12/22/2005CA2569406A1 Methods for treating mast cell disorders
12/22/2005CA2569404A1 Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
12/22/2005CA2569402A1 Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
12/22/2005CA2569395A1 Diamine .beta.2 adrenergic receptor agonists
12/22/2005CA2569352A1 Morinda citrifolia-based formulation 5-lox and 15-lox
12/22/2005CA2569178A1 Method of bowel cleansing
12/22/2005CA2569170A1 Factor viia inhibitor
12/22/2005CA2569139A1 Lapatinib with letrozole for use in a treatment of breast cancer
12/22/2005CA2569132A1 Cancer treatment method
12/22/2005CA2569113A1 Chromone derivatives useful as vanilloid antagonists
12/22/2005CA2569111A1 Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
12/22/2005CA2569036A1 Chimeric gapped oligomeric compositions
12/22/2005CA2568929A1 Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
12/22/2005CA2568856A1 Substituted tricyclic benzimidazoles
12/22/2005CA2568744A1 Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins
12/22/2005CA2568722A1 Pyrazolo pyrimidines
12/22/2005CA2568673A1 Pyridine analogs as c5a antagonists
12/22/2005CA2568632A1 Levodopa prodrugs, and compositions and uses thereof
12/22/2005CA2568625A1 System and method for transdermal delivery of an anticoagulant
12/22/2005CA2568451A1 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
12/22/2005CA2568443A1 Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihistamines
12/22/2005CA2568389A1 Hiv integrase inhibitors
1 ... 4426 4427 4428 4429 4430 4431 4432 4433 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 4446 ... 7860